PTC Therapeutics (BH3) Stock Statistics & Valuation Metrics
Total Valuation
PTC Therapeutics has a market cap or net worth of EUR 4.48B. The enterprise value is EUR 3.92B.
- Market Cap
- EUR 4.48B
- Enterprise Value
- EUR 3.92B
Share Statistics
PTC Therapeutics has 83,544,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 83,544,280
- Owned by Insiders
- 3.02%
- Owned by Institutions
- 59.63%
Financial Efficiency
PTC Therapeutics’s return on equity (ROE) is -3.32 and return on invested capital (ROIC) is 33.37%.
- Return on Equity (ROE)
- -3.32
- Return on Assets (ROA)
- 0.24
- Return on Invested Capital (ROIC)
- 33.37%
- Return on Capital Employed (ROCE)
- 0.44
- Revenue Per Employee
- 1.75M
- Profits Per Employee
- 688.84K
- Employee Count
- 991
- Asset Turnover
- 0.60
- Inventory Turnover
- 0.90
Valuation Ratios
The current PE Ratio of PTC Therapeutics is -46.47. PTC Therapeutics’s PEG ratio is 0.66.
- PE Ratio
- -46.47
- PS Ratio
- 4.40
- PB Ratio
- -26.58
- Price to FCF
- -133.99
- Price to Operating Cash Flow
- 484.60
- PEG Ratio
- 0.66
Income Statement
In the last 12 months, PTC Therapeutics had revenue of 1.73B and earned 682.64M in profits. Earnings per share was 8.58.
- Revenue
- 1.73B
- Gross Profit
- 1.66B
- Operating Income
- 856.51M
- Pretax Income
- 696.62M
- Net Income
- 682.64M
- EBITDA
- 887.66M
- Earnings Per Share (EPS)
- 8.58
Cash Flow
In the last 12 months, operating cash flow was 10.49M and capital expenditures -48.45M, giving a free cash flow of -37.96M billion.
- Operating Cash Flow
- 10.49M
- Free Cash Flow
- -37.96M
- Free Cash Flow per Share
- -0.45
Dividends & Yields
PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.75%
- Earnings Yield
- -2.09%
Stock Price Statistics
- Beta
- 0.44
- 52-Week Price Change
- -7.41%
- 50-Day Moving Average
- 57.25
- 200-Day Moving Average
- 60.54
- Relative Strength Index (RSI)
- 42.58
- Average Volume (3m)
- 100
Important Dates
PTC Therapeutics upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 23, 2027
- Ex-Dividend Date
- ―
Financial Position
PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -1318.51%
- Current Ratio
- 2.35
- Quick Ratio
- 2.27
- Debt to Market Cap
- 0.43
- Net Debt to EBITDA
- 1.94
- Interest Coverage Ratio
- 5.63
Taxes
In the past 12 months, PTC Therapeutics has paid 13.97M in taxes.
- Income Tax
- 13.97M
- Effective Tax Rate
- 0.02
Enterprise Valuation
PTC Therapeutics EV to EBITDA ratio is 29.88, with an EV/FCF ratio of -137.34.
- EV to Sales
- 4.51
- EV to EBITDA
- 29.88
- EV to Free Cash Flow
- -137.34
- EV to Operating Cash Flow
- 497.12
Balance Sheet
PTC Therapeutics has EUR 2.13B in cash and marketable securities with EUR 636.03M in debt, giving a net cash position of EUR 1.49B billion.
- Cash & Marketable Securities
- EUR 2.13B
- Total Debt
- EUR 636.03M
- Net Cash
- EUR 1.49B
- Net Cash Per Share
- EUR 17.86
- Tangible Book Value Per Share
- -EUR 8.59
Margins
Gross margin is 92.39%, with operating margin of 11.97%, and net profit margin of -9.17%.
- Gross Margin
- 92.39%
- Operating Margin
- 11.97%
- Pretax Margin
- -7.36%
- Net Profit Margin
- -9.17%
- EBITDA Margin
- 15.10%
- EBIT Margin
- 9.82%
Analyst Forecast
The average price target for PTC Therapeutics is EUR 89.54, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 89.54
- Price Target Upside
- 66.74% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- -39.87%
- EPS Growth Forecast
- -112.41%
Scores
- Smart Score
- 9
- AI Score
- ―
